Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00810602
Recruitment Status : Completed
First Posted : December 18, 2008
Results First Posted : April 11, 2014
Last Update Posted : April 11, 2014
Information provided by (Responsible Party):
Pavan Reddy, MD, University of Michigan Cancer Center

Brief Summary:

The proposed research study is to test the drug vorinostat, in a new use as an additional medication, with other standard treatments for the prevention of severe acute graft versus host disease (GVHD).

If this treatment is safe and effective, when combined with a reduced intensity transplant, the research may achieve a more effective therapy for patients with high-risk, blood cell related cancers.

All subjects will receive an identical, known treatment to test if the treatment is safe and effective (a phase II trial). For patients to take part they must have a high-risk, blood cell cancer, be suitable candidates to receive a reduced intensity transplant and have a matched, related donor.

Adult subjects (age 18 years and older) will be considered as subjects provided, as detailed in the protocol, they meet additional criteria and are not excluded from participating. About fifty (50) subjects will be enrolled in this study at the University of Michigan.

Patients who receive blood stem cell transplants (HSCT), also called bone marrow transplants, to treat their cancer are at risk for serious complications, which may sometimes be fatal. The more common, serious ones are relapse (return of their disease), body organ injury from the intensity of the chemotherapy given prior to their transplant, and a serious complication called graft versus host disease (GVHD). GVHD is a form of rejection, where the transplanted cells of the donor attack the recipient's body as foreign, and do damage to organs and tissues.

To decrease the side effects of the chemotherapy given before a transplant, reduced intensity treatment plans(regimens)have recently been developed at a number of transplant centers. A decrease in the side effects of chemotherapy (called toxicities) has been achieved; however, this success with "less intensive" treatments has been partially offset by less successful results in controlling the patient's cancer.

As mentioned above, GVHD is a form of transplant rejection. GVHD can affect the digestive system, skin, liver and other body systems. GVHD can increase the risk of infection. After a matched, related donor stem cell transplant, GVHD when severe, is a major cause of discomfort, organ damage, and even death. When a graft vs host reaction develops, but is kept under control, studies show there may be a beneficial graft versus tumor effect, helping to destroy tumor cells in the patient, and thus providing a more effective control of their cancer.

The goal of this study is to try to maximize the potential benefits, of giving patients less intense chemotherapy to reduce the toxic effects, letting the graft vs host effect help in destroying tumor cells, but preventing acute severe GVHD by using the drug vorinostat, combined with standard medicines, to reduce the chance of serious GVHD-related complications.

Condition or disease Intervention/treatment Phase
Hematologic Malignancies Graft vs Host Disease Procedure: reduced intensity, related donor stem cell transplant Drug: tacrolimus (standard GVHD prophylaxis) Drug: mycophenolate (standard GVHD prophylaxis) Drug: vorinostat Phase 1 Phase 2

Study Type : Interventional
Actual Enrollment : 61 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of Vorinostat Plus Tacrolimus & Mycophenolate to Prevent Graft Versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant
Study Start Date : January 2009
Actual Primary Completion Date : April 2013
Actual Study Completion Date : July 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Vorinostat prophylaxis
Vorinostat,combined with standard GVHD prevention medications(tacrolimus, mycophenolate) for adults who received a reduced intensity, related donor stem cell transplant
Procedure: reduced intensity, related donor stem cell transplant

Fludarabine /Busulfan(FluBu2)regimen

Fludarabine: 40 mg/m2/day in 0.9 NS, administered IV on days -5 to day -2 pre-transplant for a total of 4 doses. Busulfan: 3.2 mg/kg in 0.9 NS administered IV on days -5 and -4 for a total of 2 doses. Total body irradiation 200 cGy delivered in a single fraction will be given on day 0 for patients receiving an HLA-mismatched transplant.

Drug: tacrolimus (standard GVHD prophylaxis)
Tacrolimus will begin on day -3, IV or oral. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant

Drug: mycophenolate (standard GVHD prophylaxis)
Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.

Drug: vorinostat

Vorinostat given at a dose 100 mg PO BID starting day -10. If tolerated, vorinostat will be continued until day 100 post-transplant,whether or not acute GVHD develops.

Dose escalation/ de-escalation

Ten subjects treated at a dose of 100 mg PO BID. If dosing modifications are not required, during the pre-engraftment period in more than 4 patients, AND no more than two observed drug related toxicities CTC grade 4 or higher [probably or definitely related to the drug] then vorinostat dose will be escalated to 200 mg PO BID.

If dose escalation does not occur due to failure to meet the above criteria,then the study will enroll at the 100 mg PO BID dosing, subject to the protocol stopping rules.

If dose escalation occurs, subjects will be treated at 200 mg PO BID dosing level. If the probability of unacceptable toxicity exceeds the rules in protocol, then the dose of vorinostat will be de-escalated to 100 mg PO BID for the remainder of study.

Other Name: ZOLINZA

Primary Outcome Measures :
  1. 100-day Cumulative Incidence of Grade 2-4 Acute Graft Versus Host Disease (GVHD) [ Time Frame: 100 days ]
    Assess if the addition of Vorinostat to standard GVHD prophylaxis regimen can reduce the rate of grades 2-4 acute GVHD when compared to 48% in a cohort of identically treated RIC HSCT patients without vorinostat. A reduction of incidence to less than 25% will be considered successful.

Secondary Outcome Measures :
  1. Number of Serious Adverse Events [ Time Frame: 100 days ]
    The safety and feasibility will be partially measured by the number of serious adverse events (SAE) recorded by participants receiving at least one dose of Vorinostat.

  2. Percent Cumulative Incidence of Relapse at 2 Years. [ Time Frame: two years ]
    Determine the cumulative incidence of relapse at 2 years.

  3. Percent Survival at 2-years [ Time Frame: two years ]
    To determine 2-year overall survival rate

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have a 7/8 or 8/8 HLA A, B, C and DR, HLA-matched related donor willing and able to donate allogeneic stem cells.
  • For patients with multiple myeloma, CLL, and lymphoma: must be in CR, PR, or stable disease.
  • For MDS, acute leukemia or CML: must have <20% blasts on marrow exam.
  • For all other diseases: must have non-refractory disease.

and meet at least ONE of the next three criteria:

  • Any patient ≥ 18 years of age with a hematological malignancy and not considered a candidate for allogeneic myeloablative transplant due to illness and/or age (≥55 years).
  • Any patient ≥ 18 years of age who has relapsed following prior autologous or allogeneic transplant for a hematologic malignancy.
  • Any patient ≥ 18 years of age diagnosed with a hematological malignancy for which reduced intensity transplant is institutionally preferred over myeloablative transplant (eg, chronic lymphocytic leukemia).

Exclusion Criteria:

  • Less than 18 years of age.
  • Currently taking any HDAC inhibitors, or have taken an HDAC inhibitor within 30 days of the trial.
  • Positive serum tests for HIV, HTLV1 / HTLV2.
  • Detectable hepatitis B virus (HBV), hepatitis C (HCV) or Epstein-Barr (EBV).
  • Pregnancy.
  • One or more of the following organ system function criteria

    • Cardiac: Ejection fraction ≤ 40%
    • Renal: Estimated or actual GFR ≤ 40 ml/min (corrected for BSA)
    • Pulmonary: FEV1, FVC, or DLCO ≤ 40% predicted
    • Hepatic: Total bilirubin ≥3 mg% and AST/ALT >5 x institutional normal for age
    • Karnofsky score ≤50 (Requires considerable assistance and frequent medical care).
  • Persistent invasive infections not controlled by antimicrobial medication.
  • Any physical or psychological condition that, in the opinion of the investigator, would pose unacceptable risk to the patient.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00810602

United States, Michigan
University of Michigan Cancer Center
Ann Arbor, Michigan, United States, 48109
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
Sponsors and Collaborators
Pavan Reddy, MD
Principal Investigator: Pavan Reddy, MD University of Michigan Cancer Center

Publications of Results:
Responsible Party: Pavan Reddy, MD, Professor, University of Michigan Cancer Center Identifier: NCT00810602     History of Changes
Other Study ID Numbers: UMCC 2008.095
First Posted: December 18, 2008    Key Record Dates
Results First Posted: April 11, 2014
Last Update Posted: April 11, 2014
Last Verified: March 2014

Additional relevant MeSH terms:
Graft vs Host Disease
Immune System Diseases
Mycophenolic Acid
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antibiotics, Antineoplastic
Antineoplastic Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Histone Deacetylase Inhibitors